The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

ACMC-209ho7     1-[3,4-dihydroxy-5- (hydroxymethyl)oxolan-2...

Synonyms: Neuro_000082, NSC-146604, NSC-258350, NSC-406444, NSC-519273, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of NSC146604

 

High impact information on NSC146604

 

Chemical compound and disease context of NSC146604

 

Biological context of NSC146604

 

Anatomical context of NSC146604

 

Associations of NSC146604 with other chemical compounds

 

Gene context of NSC146604

  • A strain carrying the disrupted allele and a fui1 mutant exhibit the same phenotype as they do not grow on a medium containing uridine as the sole source of pyrimidines and as they are resistant to 10(-3) M 5-fluorouridine (5FUI), a toxic analog of uridine [31].
  • It is suggested that FdUrd exerts its anticancer effects against colon C26-10 tumors mainly through the catabolism of FdUrd to FUra by UrdPase, which then could be anabolized to 5-fluorouridine 5'-monophosphate (FUMP) by OPRTase and ultimately to other toxic 5-fluorouridine nucleotides, hence inducing the observed FdUrd toxic effects [32].
  • Inhibition of ribosomal RNA synthesis and processing by 5-fluorouridine or of general RNA synthesis by camptothecin, an inhibitor of topoisomerase I, does not affect the methylation pattern of core histones [33].
  • The activities of FdUrd phosphorylase, 5'-fluorouridine kinase, 5-fluorouridine phosphorylase, 5-fluorouracil phosphoribosyltransferase, and thymidylate synthase were not significantly different in the sensitive and resistant cell lines [34].
  • Competitive inhibitors of Psi synthases, 5-fluorouridine-containing (5-FU) wild-type and mutant U4 RNAs, were used to investigate formation of Psi in U4 RNA [35].
 

Analytical, diagnostic and therapeutic context of NSC146604

References

  1. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Klubes, P., Cerna, I. Cancer Res. (1983) [Pubmed]
  2. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Elias, L., Crissman, H.A. Cancer Res. (1988) [Pubmed]
  3. The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Wilkinson, D.S., Tlsty, T.D., Hanas, R.J. Cancer Res. (1975) [Pubmed]
  4. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Armstrong, R.D., Diasio, R.B. Cancer Res. (1980) [Pubmed]
  5. Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells. Keniry, M., Benz, C., Shafer, R.H., James, T.L. Cancer Res. (1986) [Pubmed]
  6. Effects of D-glucosamine and 6-azauridine on nucleotide contents, 5-fluorouridine uptake, and cytotoxicity in TA3 mammary tumor cells. Holstege, A., Keppler, D. J. Natl. Cancer Inst. (1986) [Pubmed]
  7. Biological consequences of incorporation of 5-fluorocytidine in the RNA of 5-fluorouracil-treated eukaryotic cells. Gleason, M.K., Fraenkel-Conrat, H. Proc. Natl. Acad. Sci. U.S.A. (1976) [Pubmed]
  8. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy. Adams, E.R., Leffert, J.J., Craig, D.J., Spector, T., Pizzorno, G. Cancer Res. (1999) [Pubmed]
  9. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Ghoshal, K., Jacob, S.T. Cancer Res. (1994) [Pubmed]
  10. Antagonistic effect of polyinosinic-polycytidylic acid on the cell lethality produced by 5-fluorouracil in human colon carcinoma cells in vitro. Iigo, M., Glazer, R.I. Cancer Res. (1985) [Pubmed]
  11. Not all pseudouridine synthases are potently inhibited by RNA containing 5-fluorouridine. Spedaliere, C.J., Mueller, E.G. RNA (2004) [Pubmed]
  12. Potentiation of antimetabolite action by uridylate trapping. Keppler, D., Holstege, A., Weckbecker, G., Fauler, J., Gasser, T. Adv. Enzyme Regul. (1985) [Pubmed]
  13. Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. Barberi-Heyob, M., Weber, B., Merlin, J.L., Dittrich, C., de Bruijn, E.A., Luporsi, E., Guillemin, F. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  14. Potentiation by dipyridamole of 5-fluorouridine antitumor activity against a rat adenocarcinoma in vivo. el Hag, I.A., Roos, G., Jönsson, P.E., Stenram, U. Anticancer Res. (1990) [Pubmed]
  15. Specific incorporation of 5-fluorocytidine into Escherichia coli RNA. Kaiser, I.I., Kladianos, D.M., Frendewey, D.A. Biochim. Biophys. Acta (1985) [Pubmed]
  16. Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases. Landis, D.M., Loeb, L.A. J. Biol. Chem. (1998) [Pubmed]
  17. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Song, D., Wientjes, M.G., Gan, Y., Au, J.L. Clin. Cancer Res. (1997) [Pubmed]
  18. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Lang, T.T., Selner, M., Young, J.D., Cass, C.E. Mol. Pharmacol. (2001) [Pubmed]
  19. Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates. Beres, J., Bentrude, W.G., Kruppa, G., McKernan, P.A., Robins, R.K. J. Med. Chem. (1985) [Pubmed]
  20. Solution structures of 5-fluorouracil-substituted RNA duplexes containing G-U wobble base pairs. Sahasrabudhe, P.V., Gmeiner, W.H. Biochemistry (1997) [Pubmed]
  21. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles. Miller, A.A., Moore, E.C., Hurlbert, R.B., Benvenuto, J.A., Loo, T.L. Cancer Res. (1983) [Pubmed]
  22. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system. Iigo, M., Kuretani, K., Hoshi, A. Cancer Res. (1983) [Pubmed]
  23. Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. Connolly, K.M., Diasio, R.B., Armstrong, R.D., Kaplan, A.M. Cancer Res. (1983) [Pubmed]
  24. The effects of the fluorinated pyrimidines FUR, FUdR, FUMP, and FdUMP on human Tenon's fibroblasts. Lee, D.A., Shapourifar-Tehrani, S., Stephenson, T.R., Kitada, S. Invest. Ophthalmol. Vis. Sci. (1991) [Pubmed]
  25. Increasing content of poly A(+) mRNA of serum-stimulated cells in the absence of ribosome synthesis. Johnson, L.F., Penman, S., Green, H. J. Cell. Physiol. (1975) [Pubmed]
  26. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment. Grant, S., Cadman, E. Cancer Res. (1982) [Pubmed]
  27. Isolation and characterization of cultured mouse T-lymphoma cells deficient in uridine-cytidine kinase. Ullman, B., Levinson, B.B., Ullman, D.H., Martin, D.W. J. Biol. Chem. (1979) [Pubmed]
  28. Inhibition of pre-mRNA splicing by 5-fluoro-, 5-chloro-, and 5-bromouridine. Sierakowska, H., Shukla, R.R., Dominski, Z., Kole, R. J. Biol. Chem. (1989) [Pubmed]
  29. First clinical experiences with a selective chemotherapy of hepatocellular carcinoma with 5-fluorouridine in combination with other antipyrimidines. Pausch, J., Holstege, A., Anukarahanonta, T., Keppler, D., Gerok, W. Adv. Enzyme Regul. (1985) [Pubmed]
  30. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Yoshisue, K., Hironaga, K., Yamaguchi, S., Yamamoto, A., Nagayama, S., Kawaguchi, Y. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  31. The ORF YBL042 of Saccharomyces cerevisiae encodes a uridine permease. Wagner, R., de Montigny, J., de Wergifosse, P., Souciet, J.L., Potier, S. FEMS Microbiol. Lett. (1998) [Pubmed]
  32. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10. Ashour, O.M., Naguib, F.N., Goudgaon, N.M., Schinazi, R.F., el Kouni, M.H. Biochem. Pharmacol. (2000) [Pubmed]
  33. Transcriptional inhibitors affecting topoisomerase II induce changes in histone methylation patterns similar to those induced by heat shock. Desrosiers, R., Tanguay, R.M. Biochem. Biophys. Res. Commun. (1989) [Pubmed]
  34. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. Sobrero, A.F., Moir, R.D., Bertino, J.R., Handschumacher, R.E. Cancer Res. (1985) [Pubmed]
  35. Modification of human U4 RNA requires U6 RNA and multiple pseudouridine synthases. Zerby, D.B., Patton, J.R. Nucleic Acids Res. (1997) [Pubmed]
  36. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Glazer, R.I., Lloyd, L.S. Mol. Pharmacol. (1982) [Pubmed]
  37. Glaucoma filtration surgery in monkeys using 5-fluorouridine in polyanhydride disks. Jampel, H.D., Leong, K.W., Dunkelburger, G.R., Quigley, H.A. Arch. Ophthalmol. (1990) [Pubmed]
  38. Identification and quantitation of 5-fluorouridine in rat urine after administration of 5-fluorouracil or 5-fluoro-2'-deoxyuridine. Gelijkens, C.F., Sandra, P., Belpaire, F., De Leenheer, A.P. Drug Metab. Dispos. (1980) [Pubmed]
  39. Determination of the concentrations of 5-fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography. Del Nozal, M.J., Bernal, J.L., Pampliega, A., Marinero, P., Pozuelo, M. J. Chromatogr. B, Biomed. Appl. (1994) [Pubmed]
 
WikiGenes - Universities